{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:09:17Z","timestamp":1776866957934,"version":"3.51.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have had a revolutionary effect on the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially squamous cell lung cancer. However, ICIs may cause associated immune-related adverse events (ir-AEs). No case of sintilimab-induced toxic epidermal necrolysis (TEN) has been reported. In this report, we discussed a patient with advanced NSCLC and comorbid pulmonary tuberculosis who underwent immunotherapy and chemotherapy as neoadjuvant therapy and anti-tuberculosis therapy concurrently. Partial response (PR) of the tumor was achieved after three cycles of neoadjuvant therapy without cutaneous toxicities. Video-assisted thoracoscopic surgery (VATS) left lower lobectomy was performed successfully. Sintilimab and chemotherapy were administered as adjuvant therapy, after which the patient suffered severe TEN that rapidly progressed to cover &amp;gt;50% of the skin. TEN was associated with extensive rashes of the trunk and pruritus. With history of sintilimab use, clinical symptoms, and physical examination, TEN was diagnosed. Intravenous methylprednisolone and oral prednisone were administered until the patient totally recovered from the cutaneous toxicities caused by sintilimab. Monitoring of such rare but severe cutaneous toxicities is essential in patients who are treated with sintilimab.<\/jats:p>","DOI":"10.3389\/fimmu.2022.989966","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T09:56:36Z","timestamp":1661507796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Gang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00056","article-title":"Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers","volume":"7","author":"Maughan","year":"2017","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00818-1","article-title":"Safety and efficacy of neoadjuvant immune checkpoint inhibitor therapy in patients with resectable non-small-cell lung cancer: A systematic review","volume":"16","author":"Zhao","year":"2021","journal-title":"Target Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633522","article-title":"Efficacy of combination chemo-immunotherapy as a first-line treatment for advanced non-small cell lung cancer patients with HER-2 alterations: a case series","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-524","article-title":"The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with mycobacterium tuberculosis infection","volume":"10","author":"Shi","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.21037\/atm-21-6899","article-title":"Adverse events of different PD-1 inhibitors in lung cancer patients: a real world study","volume":"10","author":"Zheng","year":"2022","journal-title":"Ann Transl Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102983","DOI":"10.1016\/j.critrevonc.2020.102983","article-title":"Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities","volume":"152","author":"Garrtee","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S193338","article-title":"Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients","volume":"15","author":"Zhou","year":"2019","journal-title":"Ther Clin Risk Manage"},{"key":"B9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000492172","article-title":"Atezolizumab-induced stevens-Johnson syndrome in a patient with non-small cell lung carcinoma","volume":"10","author":"Chirasuthat","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.80272","article-title":"Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors","volume":"36","author":"Grazyna","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jtos.2021.06.010","article-title":"Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated stevens-Johnson syndrome\/toxic epidermal necrolysis in cancer patients","volume":"22","author":"Ma","year":"2021","journal-title":"Ocul Surf"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.06.033","article-title":"Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: a case study","volume":"147","author":"Yoon","year":"2020","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S347852","article-title":"Predictive factors correlated with the development of immune-related adverse events in patients with non-small cell lung cancer treated with immune checkpoint inhibitor","volume":"2","author":"Sonehara","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33822","article-title":"Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of non-small cell lung cancer patients","volume":"150","author":"Huang","year":"2022","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.24920\/31805","article-title":"Treatment of skin reaction induced by nivolumab combined with radiotherapy in non-small cell lung cancer: A case report","volume":"33","author":"Zhao","year":"2018","journal-title":"Chin Med Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/annrheumdis-2020-218149","article-title":"Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data","volume":"81","author":"Singh","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000505353","article-title":"A case of nivolumab-induced cutaneous toxicity with multiple morphologies","volume":"6","author":"Nguyen","year":"2020","journal-title":"Dermatopathology(Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01459-7","article-title":"A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis","volume":"14","author":"Naito","year":"2021","journal-title":"Clin J Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.989966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T09:56:37Z","timestamp":1661507797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.989966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2022.989966"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.989966","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"article-number":"989966"}}